CN103476410B - 联合疗法 - Google Patents

联合疗法 Download PDF

Info

Publication number
CN103476410B
CN103476410B CN201280004616.5A CN201280004616A CN103476410B CN 103476410 B CN103476410 B CN 103476410B CN 201280004616 A CN201280004616 A CN 201280004616A CN 103476410 B CN103476410 B CN 103476410B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
ccr2
blocker
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280004616.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103476410A (zh
Inventor
K·D·G·福莱格
E·麦考尔
J·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimerix Bioscience Pty Ltd
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46506697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103476410(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2011900060A external-priority patent/AU2011900060A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Priority to CN201711107879.XA priority Critical patent/CN107899012A/zh
Publication of CN103476410A publication Critical patent/CN103476410A/zh
Application granted granted Critical
Publication of CN103476410B publication Critical patent/CN103476410B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201280004616.5A 2011-01-11 2012-01-11 联合疗法 Active CN103476410B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711107879.XA CN107899012A (zh) 2011-01-11 2012-01-11 联合疗法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2011900060A AU2011900060A0 (en) 2011-01-11 Combination Therapy
AU2011900060 2011-01-11
US201161432896P 2011-01-14 2011-01-14
US61/432,896 2011-01-14
US201161547951P 2011-10-17 2011-10-17
AU2011904279 2011-10-17
US61/547,951 2011-10-17
AU2011904279A AU2011904279A0 (en) 2011-10-17 Combination Therapy
PCT/AU2012/000014 WO2012094703A1 (en) 2011-01-11 2012-01-11 Combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711107879.XA Division CN107899012A (zh) 2011-01-11 2012-01-11 联合疗法

Publications (2)

Publication Number Publication Date
CN103476410A CN103476410A (zh) 2013-12-25
CN103476410B true CN103476410B (zh) 2020-02-21

Family

ID=46506697

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280004616.5A Active CN103476410B (zh) 2011-01-11 2012-01-11 联合疗法
CN201711107879.XA Pending CN107899012A (zh) 2011-01-11 2012-01-11 联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711107879.XA Pending CN107899012A (zh) 2011-01-11 2012-01-11 联合疗法

Country Status (9)

Country Link
US (6) US9314450B2 (enExample)
EP (4) EP4215194B1 (enExample)
JP (4) JP6087836B2 (enExample)
CN (2) CN103476410B (enExample)
AU (1) AU2012206945B2 (enExample)
CA (1) CA2821985C (enExample)
IL (1) IL227414A (enExample)
WO (1) WO2012094703A1 (enExample)
ZA (1) ZA201305897B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382915B2 (en) 2017-10-11 2022-07-12 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
US12194032B2 (en) 2016-11-23 2025-01-14 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2793657A1 (en) 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014075096A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
HK1216233A1 (zh) 2013-02-28 2016-10-28 参天制药株式会社 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼後段疾病的预防或治疗剂
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
EP2961483A4 (en) * 2013-03-01 2017-03-08 The Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US20170202845A1 (en) * 2014-07-17 2017-07-20 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for a posterior ocular disease
JP2017526713A (ja) * 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN108218789A (zh) * 2018-03-12 2018-06-29 钦州学院 碳13氘代甲基替米沙坦及其制备方法和用途
WO2019241590A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020213665A1 (ja) * 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
AU2020351826A1 (en) * 2019-09-26 2022-03-10 Dimerix Bioscience Pty Ltd Method and composition for the treatment of disease
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
US20230165838A1 (en) * 2020-05-06 2023-06-01 Dimerix Bioscience Ltd. Treatment for acute respiratory distress syndrome
CN117042763A (zh) * 2021-03-23 2023-11-10 戴麦里克斯生物科学有限公司 炎性疾病的治疗
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd
IL320391A (en) * 2022-10-24 2025-06-01 Hadasit Med Res Service Modulators and uses thereof
TW202444344A (zh) * 2023-05-12 2024-11-16 澳大利亞商迪美力士生物科技有限公司 用於腎病之治療調配物
CN117054652B (zh) * 2023-08-04 2024-05-17 南京医科大学 一种用于辅助检测心肌肥厚的生物标志物及其应用
EP4686469A1 (en) * 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
US5492904A (en) 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH059116A (ja) 1991-07-01 1993-01-19 Sanwa Kagaku Kenkyusho Co Ltd ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
CN1192696A (zh) * 1995-06-07 1998-09-09 G·D·瑟尔公司 用于充血性心力衰竭治疗的螺甾内酯与血管紧张素ⅱ拮抗药组合疗法
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
DE60130538T2 (de) * 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
US7262185B2 (en) 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
EP1481996A1 (en) 2003-05-30 2004-12-01 KRATON Polymers Research B.V. Process for making a coupled block copolymer composition
US7049076B2 (en) 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
CA2546764A1 (en) 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
KR20070053239A (ko) * 2004-09-06 2007-05-23 코와 가부시키가이샤 사구체 질환 치료제
PE20060594A1 (es) 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
WO2008056313A1 (en) 2006-11-10 2008-05-15 Koninklijke Philips Electronics N.V. Preventing quench in a magnetic resonance examination system
WO2008055313A1 (en) 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Detection system and uses therefor
CN101534824A (zh) * 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
MX2010003113A (es) 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
EP2252327A2 (en) * 2007-12-04 2010-11-24 Schering Corporation Methods of treating copd
US20110092463A1 (en) * 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
US8537791B2 (en) 2009-01-20 2013-09-17 Lg Electronics Inc. Method and apparatus for channel access in contention-based communication system and station
JP2012521967A (ja) * 2009-03-27 2012-09-20 ディメリックス バイオサイエンス ピーティーワイ リミテッド 新規な受容体のヘテロ二量体／ヘテロオリゴマー

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C-C亚族趋化因子与糖尿病肾病;吕秀娟;《国际内科学杂志》;20090430;第36卷(第4期);192-195 *
厄贝沙坦治疗2型糖尿病肾病的临床疗效观察;孙慧君;《临床医学工程》;20100630;第17卷(第6期);28-29 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194032B2 (en) 2016-11-23 2025-01-14 Chemocentryx, Inc. Method of treating focal segmental glomerulosclerosis
US11382915B2 (en) 2017-10-11 2022-07-12 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists

Also Published As

Publication number Publication date
US20130289084A1 (en) 2013-10-31
JP2017078085A (ja) 2017-04-27
EP4215194A1 (en) 2023-07-26
US20220323418A1 (en) 2022-10-13
IL227414A (en) 2017-06-29
EP2663304A4 (en) 2014-06-25
CN107899012A (zh) 2018-04-13
WO2012094703A1 (en) 2012-07-19
US11382896B2 (en) 2022-07-12
US10525038B2 (en) 2020-01-07
EP2663304B1 (en) 2019-11-20
US20160243127A1 (en) 2016-08-25
EP4711006A2 (en) 2026-03-18
US20180000826A1 (en) 2018-01-04
CA2821985A1 (en) 2012-07-19
EP2663304A1 (en) 2013-11-20
US9314450B2 (en) 2016-04-19
AU2012206945B2 (en) 2015-02-19
US20240366570A1 (en) 2024-11-07
ZA201305897B (en) 2014-04-30
JP6087836B2 (ja) 2017-03-01
US10058555B2 (en) 2018-08-28
JP2014505049A (ja) 2014-02-27
US20200046685A1 (en) 2020-02-13
CA2821985C (en) 2019-07-09
JP2018127498A (ja) 2018-08-16
EP4215194B1 (en) 2026-03-25
JP2020122015A (ja) 2020-08-13
IL227414A0 (en) 2013-09-30
CN103476410A (zh) 2013-12-25
EP3586844A1 (en) 2020-01-01
US12083102B2 (en) 2024-09-10
AU2012206945A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
US12083102B2 (en) Method for treating inflammatory disorders
EP4494701A2 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US20220226293A1 (en) Treatments of angioedema
US20230381162A1 (en) Treatments of angioedema
TW201004927A (en) Piperidinyl derivative as a modulator of chemokine receptor activity
CN117042763A (zh) 炎性疾病的治疗
CN114466653A (zh) 用于治疗疾病的方法和组合物
WO2021222972A1 (en) Treatment for acute respiratory distress syndrome
HK1192712A (en) Combination therapy
HK1192712B (en) Combination therapy
ES2770785T3 (es) Terapia de combinación
WO2021222971A1 (en) Treatment for virus induced acute respiratory distress syndrome
HK40115215A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
JP2010031006A (ja) 有機化合物の使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant